Humacyte Balance Sheet Health

Financial Health criteria checks 2/6

Humacyte has a total shareholder equity of $-63.7M and total debt of $62.4M, which brings its debt-to-equity ratio to -97.9%. Its total assets and total liabilities are $114.8M and $178.5M respectively.

Key information

-97.9%

Debt to equity ratio

US$62.37m

Debt

Interest coverage ration/a
CashUS$20.57m
Equity-US$63.72m
Total liabilitiesUS$178.49m
Total assetsUS$114.76m

Recent financial health updates

Recent updates

Humacyte's Symvess Debut: A Milestone With Lingering Concerns (Rating Downgrade)

Dec 23

Humacyte: FDA Waiting Game Bleeding Company Dry

Dec 14

Humacyte: Navigating The FDA Uncertainty And ATEV's Potential

Sep 24

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Aug 16
Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Humacyte: Pioneering Vascular Solutions With High-Stakes Potential

Jul 17

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Jun 05
Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

May 14

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Feb 14
Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Financial Position Analysis

Short Term Liabilities: HUMA has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: HUMA has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: HUMA has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: HUMA's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HUMA has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: HUMA is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 03:55
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Humacyte, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bruce JacksonBenchmark Company
Michael GormanBTIG
Kristen KluskaCantor Fitzgerald & Co.